BIOCON
|
BIOCON Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 3.85 | 5.40 | 6.17 | 6.24 | 15.09 |
| CEPS(Rs) | 14.63 | 13.21 | 13.01 | 12.10 | 12.09 |
| DPS(Rs) | 1.50 | 0.50 | - | - | 1.00 |
| Book NAV/Share(Rs) | 146.53 | 68.53 | 62.27 | 54.97 | 100.33 |
| Tax Rate(%) | 28.32 | 21.51 | 20.75 | 25.94 | 17.47 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 18.80 | 18.18 | 18.23 | 19.95 | 20.38 |
| EBIT Margin(%) | 11.67 | 12.80 | 15.76 | 20.31 | 23.32 |
| Pre Tax Margin(%) | 7.96 | 11.98 | 14.95 | 19.28 | 22.03 |
| PAT Margin (%) | 5.70 | 9.40 | 11.85 | 14.28 | 18.18 |
| Cash Profit Margin (%) | 15.57 | 19.32 | 21.86 | 23.05 | 26.30 |
| Performance Ratios | |||||
| ROA(%) | 1.79 | 4.03 | 5.24 | 6.94 | 9.26 |
| ROE(%) | 4.98 | 9.83 | 12.03 | 14.26 | 18.01 |
| ROCE(%) | 5.37 | 8.30 | 10.56 | 14.35 | 16.12 |
| Asset Turnover(x) | 0.31 | 0.43 | 0.44 | 0.49 | 0.51 |
| Sales/Fixed Asset(x) | 0.48 | 0.77 | 0.74 | 0.78 | 0.85 |
| Working Capital/Sales(x) | 2.95 | 1.80 | 2.11 | 4.78 | 2.98 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 2.06 | 1.31 | 1.36 | 1.29 | 1.18 |
| Receivable days | 91.14 | 79.19 | 69.67 | 72.86 | 77.96 |
| Inventory Days | 105.87 | 92.60 | 84.38 | 71.47 | 58.05 |
| Payable days | 278.58 | 209.62 | 230.92 | 231.48 | 212.04 |
| Valuation Parameters | |||||
| PER(x) | 53.54 | 61.95 | 66.25 | 43.40 | 20.25 |
| PCE(x) | 14.11 | 25.33 | 31.42 | 22.36 | 25.28 |
| Price/Book(x) | 1.41 | 4.88 | 6.57 | 4.92 | 6.09 |
| Yield(%) | 0.73 | 0.15 | - | - | 0.16 |
| EV/Net Sales(x) | 3.59 | 5.29 | 7.20 | 5.41 | 6.89 |
| EV/Core EBITDA(x) | 13.90 | 19.85 | 26.95 | 19.32 | 24.71 |
| EV/EBIT(x) | 30.50 | 41.23 | 45.67 | 26.64 | 29.56 |
| EV/CE(x) | 0.78 | 2.16 | 2.82 | 2.42 | 3.20 |
| M Cap / Sales | 2.22 | 4.91 | 6.87 | 5.15 | 6.65 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 36.54 | 14.57 | 13.37 | 14.26 | 33.73 |
| Core EBITDA Growth(%) | 32.28 | 14.45 | 8.09 | 14.72 | 48.57 |
| EBIT Growth(%) | 25.26 | -6.64 | -12.06 | -0.47 | 91.48 |
| PAT Growth(%) | -16.67 | -8.82 | -5.96 | -10.25 | 121.28 |
| EPS Growth(%) | -28.64 | -12.48 | -1.03 | -58.68 | 143.10 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 1.01 | 0.60 | 0.58 | 0.40 | 0.40 |
| Current Ratio(x) | 1.45 | 2.19 | 1.81 | 1.33 | 1.61 |
| Quick Ratio(x) | 0.95 | 1.59 | 1.37 | 0.97 | 1.29 |
| Interest Cover(x) | 3.14 | 15.54 | 19.50 | 19.72 | 18.14 |
| Total Debt/Mcap(x) | 0.72 | 0.12 | 0.09 | 0.08 | 0.07 |
Compare Financial Ratios of peers of BIOCON
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BIOCON | ₹35,021.5 Cr | 11.5% | 17.3% | 26.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,831.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
| CIPLA | ₹113,471.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,713.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,960.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,687.8 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics | |
BIOCON Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BIOCON | 11.5% |
17.3% |
26.6% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
